The North America Narcolepsy Therapeutics Market is expected to witness market growth of 9.8% CAGR during the forecast period (2022-2028).
There are two different forms of narcolepsy recognized by the International Classification of Sleep Disorders-Third Edition diagnostic criteria: type 1 and type 2. Chronic daily extreme sleepiness lasting less than three months, mean sleep latency of fewer than eight minutes, and two or more sleep-onset rapid eye movements on the Multiple Sleep Latency Test are all criteria that all types share. The cataplexy and/or low levels of hypocretin 1 in the cerebrospinal fluid (CSF) are additional diagnostic criteria for NT1 (orexin A).
The NT2 criteria include the absence of cataplexy, normal or unmeasured levels of hypocretin 1 in the CSF and the absence of any other condition (including medication side effects or discontinuation) that could explain the results of the EDS and/or MSLT. Many people who have narcolepsy also have unsteady, interrupted sleep, which can include frequent nighttime awakenings. The daily activities of narcoleptics can be affected. People who have narcolepsy may unintentionally nod off while engaging in activities like talking, eating, or driving.
The treatment for sleep disorders is in greater demand in both the United States and Canada. The market is expected to be driven by the rising prevalence of narcoleptic disorders, higher awareness, and high healthcare spending. The other elements projected to support revenue growth include favorable reimbursement regulations for treatments, a solid clinical pipeline, and rising stress levels. The high frequency of narcolepsy in industrialized nations like the United States is expected to encourage more people to use narcolepsy treatments, fueling the expansion of this market.
The US market dominated the North America Narcolepsy Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,071.6 million by 2028.The Canada market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 11.3% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
There are two different forms of narcolepsy recognized by the International Classification of Sleep Disorders-Third Edition diagnostic criteria: type 1 and type 2. Chronic daily extreme sleepiness lasting less than three months, mean sleep latency of fewer than eight minutes, and two or more sleep-onset rapid eye movements on the Multiple Sleep Latency Test are all criteria that all types share. The cataplexy and/or low levels of hypocretin 1 in the cerebrospinal fluid (CSF) are additional diagnostic criteria for NT1 (orexin A).
The NT2 criteria include the absence of cataplexy, normal or unmeasured levels of hypocretin 1 in the CSF and the absence of any other condition (including medication side effects or discontinuation) that could explain the results of the EDS and/or MSLT. Many people who have narcolepsy also have unsteady, interrupted sleep, which can include frequent nighttime awakenings. The daily activities of narcoleptics can be affected. People who have narcolepsy may unintentionally nod off while engaging in activities like talking, eating, or driving.
The treatment for sleep disorders is in greater demand in both the United States and Canada. The market is expected to be driven by the rising prevalence of narcoleptic disorders, higher awareness, and high healthcare spending. The other elements projected to support revenue growth include favorable reimbursement regulations for treatments, a solid clinical pipeline, and rising stress levels. The high frequency of narcolepsy in industrialized nations like the United States is expected to encourage more people to use narcolepsy treatments, fueling the expansion of this market.
The US market dominated the North America Narcolepsy Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,071.6 million by 2028.The Canada market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 11.3% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type- Narcolepsy with Cataplexy
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- Others
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Bioprojet
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Narcolepsy Therapeutics Market by Type
Chapter 4. North America Narcolepsy Therapeutics Market by Product
Chapter 5. North America Narcolepsy Therapeutics Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Bioprojet
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Methodology
LOADING...
